NCT01779882View on ClinicalTrials.gov

Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT

NACompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 6, 2018

Study Completion Date

January 6, 2018

Conditions
Myeloid LeukemiaPrecursor Myeloid NeoplasmsLymphoid Neoplasms
Interventions
DRUG

Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation

Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.

DRUG

Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation

Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.

Trial Locations (3)

1205

University Hospital Geneva, Geneva

4031

University Hospital, Basel, Basel

8091

University Hospital Zurich, Zurich

All Listed Sponsors
collaborator

University Hospital, Zürich

OTHER

collaborator

University Hospital, Geneva

OTHER

lead

University Hospital, Basel, Switzerland

OTHER

NCT01779882 - Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT | Biotech Hunter | Biotech Hunter